Quanex Building Products Corpor

Valuation Analysis

About the Company

Quanex Building Products Corpor en bref

Quanex Building Products Corpor (NX) is currently trading at 14,82 € with a market capitalization of 681 M €. The 52-week range spans from 9,62 € to 20,03 €; the current price is 26% below the yearly high. Year-over-year revenue growth stands at +2.2%.

💰 Dividende

Quanex Building Products Corpor currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

4 analystes évaluent Quanex Building Products Corpor (NX) au consensus : Achat Fort. L'objectif de cours moyen est de 23,76 €, soit un potentiel de +60.29% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 21,79 € à 26,15 €.

Quanex Building Products Corpor : la thèse d'investissement en détail

Quanex Building Products Corpor (NX) operates in the Industrials — specifically Building Products & Equipment — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Wall Street consensus sits at Strong Buy with an average price target implying roughly 60.29% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

Revenue growth has slowed to just 2.2%, which is below nominal GDP — the business is no longer outgrowing the broader economy. Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders.

Valorisation en contexte

With a PEG ratio of 0.72, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity. The EV/EBITDA multiple of 7.67x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.

À surveiller

• The analyst consensus price target implies 60.29% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price shows short-term weakness (below 50d MA) but is still in a longer-term uptrend (above 200d MA).

Profil de risque

The data points to relatively defensive market behavior, elevated short interest (8.2%), higher leverage relative to equity.

Trading Data

Related Stocks in the Same Sector

Where can I buy Quanex Building Products Corpor?

Compare top-rated brokers — low fees, trusted providers, fully regulated.